Breaking News on Global Pharmaceutical Technology & Manufacturing

Report abuse about a comment

Project should include participation by supply chain partners

Counterfeiting is a priority across the phamaceutical supply chain. Serialization and Pedigree requirements and solutions are still evolving. I would like to see participation in these types of projects by Manufacturers, Distributors, Retailers and Consumers. Also, the many standards determining bodies, i.e, GS1, HDMA, etc. should be connected to the effort. There needs to be a holistic approach that ties together the many requirements and regulations into one universal solution with defined standards. Many supply chain partners are looking to 2015 and the California mandate. This effort should be synergistic with state and federal regulations.

Posted by Bill Ricigliano
14 October 2010 | 14h31

Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.

Your name *
Your email *

We will not publish your email on the site

Reason *

Back to: FDA & WHO collaborate on surveillance of counterfeit drugs

Spotlight

Exporters rush to meet Chinese FDA serialisation requirements

Exporters rush to meet Chinese FDA serialisation requirements

Pharmaceutical companies are rushing to respond to shortened deadlines from China’s Food and Drug Administration (CFDA) for...

GSK confident despite endotoxin problems at Canadian vaccine plant

GSK confident despite ongoing endotoxin problems at Canadian flu vaccine plant

GSK is confident it can meet Flulaval production targets ahead of this winter’s flu season despite ongoing...

Marketing agency targets poor interns for GSK paid trials

Marketing agency targets poor interns for GSK paid trials

Representatives for GSK have targeted struggling graduates and unpaid interns as volunteers for clinical trials, saying the...

Roche: ‘If suppliers don’t open up their books, then we are done’

Roche: ‘If suppliers don’t open up their books, then we are done’

Drug raw materials suppliers have not recognised their potential value to biopharmaceutical customers according to Roche which...

Teva's 70+ manufacturing sites could be halved in efficiency drive

Teva's 70+ manufacturing sites could be halved in efficiency drive

Teva could halve its manufacturing network as part of its $2bn-a-year efficiency programme says CFO Eyal Desheh,...

Key Industry Events

 

Access all events listing

Our events, Events from partners...